See more : China Finance Online Co. Limited (JRJC) Income Statement Analysis – Financial Results
Complete financial analysis of Molecular Partners AG (MOLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Molecular Partners AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Twenty Seven Co. Limited (TSC.AX) Income Statement Analysis – Financial Results
- Aptinyx Inc. (APTX) Income Statement Analysis – Financial Results
- Intact Financial Corporation (INFFF) Income Statement Analysis – Financial Results
- Toyoda Gosei Co., Ltd. (TGOSY) Income Statement Analysis – Financial Results
- Many Bright Ideas Technologies Inc. (MBGNF) Income Statement Analysis – Financial Results
Molecular Partners AG (MOLN)
About Molecular Partners AG
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.04M | 189.56M | 9.33M | 9.34M | 20.38M | 10.36M | 20.02M | 23.04M | 29.12M | 26.63M | 32.42M |
| Cost of Revenue | 47.84M | 50.75M | 55.72M | 56.08M | 43.50M | 15.60M | 17.82M | 14.57M | 1.17M | 170.75K | 1.22M |
| Gross Profit | -40.81M | 138.81M | -46.39M | -46.73M | -23.12M | -5.25M | 2.19M | 8.47M | 27.95M | 26.45M | 31.20M |
| Gross Profit Ratio | -579.80% | 73.23% | -497.19% | -500.12% | -113.40% | -50.67% | 10.96% | 36.76% | 96.00% | 99.36% | 96.23% |
| Research & Development | 48.78M | 50.75M | 55.72M | 56.08M | 43.50M | 38.20M | 37.45M | 35.19M | 23.92M | 18.79M | 20.82M |
| General & Administrative | 19.00M | 21.82M | 16.91M | 11.03M | 13.16M | 9.46M | 8.28M | 7.24M | 6.22M | 4.90M | 3.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 57.00K | 5.23M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 84.54K |
| SG&A | 19.00M | 21.82M | 16.91M | 11.03M | 13.16M | 9.46M | 8.28M | 7.24M | 6.22M | 4.90M | 3.59M |
| Other Expenses | -47.48M | 372.00K | 125.00K | 568.00K | 381.00K | -9.76M | -12.12M | -9.38M | 4.16M | 4.29M | 2.29M |
| Operating Expenses | 20.30M | 72.94M | 72.75M | 67.67M | 57.04M | 47.77M | 45.86M | 42.53M | 31.34M | 24.78M | 25.30M |
| Cost & Expenses | 68.15M | 72.94M | 72.75M | 67.67M | 57.04M | 47.77M | 45.86M | 42.53M | 31.34M | 24.78M | 25.30M |
| Interest Income | 4.28M | 1.14M | 99.00K | 367.00K | 1.60M | 693.00K | 610.00K | 335.00K | 357.52K | 347.85K | 234.82K |
| Interest Expense | 49.00K | 605.00K | 548.00K | 271.00K | 27.00K | 591.00K | 197.00K | 89.00K | 216.00 | 853.00 | 226.53K |
| Depreciation & Amortization | 2.42M | 2.39M | 2.57M | 2.89M | 2.47M | 924.00K | 1.15M | 1.09M | 909.39K | 809.53K | 793.02K |
| EBITDA | -59.53M | 120.85M | -60.85M | -59.59M | -33.71M | -36.27M | -24.70M | -18.06M | -1.02M | -1.47M | 7.93M |
| EBITDA Ratio | -845.84% | 63.37% | -651.25% | -589.73% | -160.26% | -350.25% | -120.35% | -78.39% | -3.51% | 11.23% | 25.10% |
| Operating Income | -61.11M | 116.61M | -63.42M | -58.33M | -36.66M | -37.41M | -25.84M | -19.49M | -2.22M | 1.84M | 7.12M |
| Operating Income Ratio | -868.26% | 61.52% | -679.72% | -624.21% | -179.86% | -361.27% | -129.12% | -84.57% | -7.62% | 6.91% | 21.95% |
| Total Other Income/Expenses | -876.00K | 1.24M | -365.00K | -4.45M | 389.00K | 374.00K | 414.00K | 874.00K | 2.07M | -4.12M | 24.93K |
| Income Before Tax | -61.98M | 117.85M | -63.78M | -62.78M | -36.27M | -37.04M | -25.43M | -18.61M | -148.82K | -2.28M | 7.14M |
| Income Before Tax Ratio | -880.70% | 62.17% | -683.63% | -671.82% | -177.95% | -357.66% | -127.05% | -80.78% | -0.51% | -8.57% | 22.03% |
| Income Tax Expense | 0.00 | -1.24M | 2.00K | -11.00K | 17.00K | -591.00K | -414.00K | -874.00K | -2.07M | 4.12M | -226.53K |
| Net Income | -61.98M | 117.85M | -63.79M | -62.76M | -36.29M | -37.04M | -25.43M | -18.61M | -148.82K | -2.28M | 7.14M |
| Net Income Ratio | -880.70% | 62.17% | -683.65% | -671.70% | -178.03% | -357.66% | -127.05% | -80.78% | -0.51% | -8.57% | 22.03% |
| EPS | -1.89 | 3.63 | -2.06 | -2.51 | -1.69 | -1.75 | -1.22 | -0.91 | -0.01 | -0.15 | 0.37 |
| EPS Diluted | -1.89 | 3.54 | -2.06 | -2.51 | -1.69 | -1.75 | -1.22 | -0.91 | -0.01 | -0.15 | 0.37 |
| Weighted Avg Shares Out | 32.77M | 32.47M | 31.01M | 25.00M | 21.41M | 21.17M | 20.86M | 20.43M | 19.54M | 15.22M | 19.49M |
| Weighted Avg Shares Out (Dil) | 32.77M | 33.27M | 31.01M | 25.00M | 21.41M | 21.17M | 20.86M | 20.43M | 19.54M | 15.29M | 19.49M |
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
Molecular Partners to Present at SVB Leerink Global Healthcare Conference
Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences
Molecular Partners AG (MOLN) Q2 2022 Earnings Call Transcript
Molecular Partners to Participate in Upcoming Healthcare Investor Conferences
Why Molecular Partners Shares Are Falling
Why Molecular Partners Shares Are Getting Hammered
Molecular Partners shares tumble 37% after Amgen returns rights to tumor treatment candidate
Molecular Partners Regains Rights To Early-Stage Cancer Asset From Amgen
Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data
Source: https://incomestatements.info
Category: Stock Reports